Fuji Pharma Co., Ltd.

Tokyo Stock Exchange 4554.T

Fuji Pharma Co., Ltd. Debt to Equity Ratio for the year ending September 30, 2024: 0.64

Fuji Pharma Co., Ltd. Debt to Equity Ratio is 0.64 for the year ending September 30, 2024, a -8.67% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Fuji Pharma Co., Ltd. Debt to Equity Ratio for the year ending September 30, 2023 was 0.70, a 2.45% change year over year.
Fuji Pharma Co., Ltd. Debt to Equity Ratio for the year ending September 30, 2022 was 0.69, a 20.17% change year over year.
Fuji Pharma Co., Ltd. Debt to Equity Ratio for the year ending September 30, 2021 was 0.57, a 87.19% change year over year.
Fuji Pharma Co., Ltd. Debt to Equity Ratio for the year ending September 30, 2020 was 0.31, a 10.02% change year over year.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

Tokyo Stock Exchange: 4554.T

Fuji Pharma Co., Ltd.

CEO	Mr. Toyoyuki Kamide
IPO Date	Feb. 22, 2010
Location	Japan
Headquarters	5-7 Sanban-cho
Employees	1,621
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cleaning Supplies Clinical Trials Cosmetics Drugstores & Retail Pharmacies Medical Instruments Personal Care

Description

Fuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers injection agents, internal drugs, drugs for external use, and diagnostic products. It also provides medical care for women; in vitro diagnostics, acute medical care products, and curative medicines; and information regarding pharmaceuticals and health. Fuji Pharma Co., Ltd. was incorporated in 1965 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years